Melanoma and neural system tumor syndrome

Melanoma and neural system tumor syndrome, also known as melanoma-astrocytoma syndrome, is a rare hereditary cancer predisposition syndrome characterized by an increased susceptibility to developing both cutaneous malignant melanoma and tumors of the central nervous system, particularly astrocytomas and other neural system neoplasms. This condition is caused by germline deletions or mutations affecting the CDKN2A (cyclin-dependent kinase inhibitor 2A) gene region on chromosome 9p21, which plays a critical role in cell cycle regulation and tumor suppression. Some cases also involve alterations in adjacent genes in this chromosomal region. The syndrome primarily affects the skin and the central nervous system. Patients may develop malignant melanoma of the skin, often at a relatively young age or with multiple primary melanomas, alongside nervous system tumors such as astrocytomas, glioblastomas, or other gliomas. Additional tumor types, including meningiomas and nerve sheath tumors, have also been reported in some families. The clinical presentation is variable, and not all mutation carriers will develop both tumor types; some individuals may present with only melanoma or only a neural system tumor. There is no specific curative treatment for the underlying genetic predisposition. Management focuses on heightened cancer surveillance, including regular dermatologic examinations with dermoscopy for early melanoma detection and neurological monitoring with brain MRI when clinically indicated. Treatment of individual tumors follows standard oncologic protocols, including surgical excision, chemotherapy, and radiation therapy as appropriate. Genetic counseling is recommended for affected families to inform at-risk relatives about screening options and inheritance risks.

Common questions about Melanoma and neural system tumor syndrome